Managing Rheumatoid Arthritis: Spotlight on New and Emerging Therapies

Using interactive videos, downloadable slides, and ClinicalThought commentaries, hear from expert faculty members as they explore guideline-recommended therapeutic strategies for RA and the latest data on and clinical impact of Janus kinases inhibitors.
Gregg J. Silverman, MD
Program Director
Roy Fleischmann, MD
Cesar E. Fors Nieves, MD
William F. C. Rigby, MD
Eric M. Ruderman, MD
Sergio Schwartzman, MD
Gregg J. Silverman, MD

RA Management

In this downloadable slideset, Gregg J. Silverman, MD, and Sergio Schwartzman, MD, discuss approaches to integrating the latest ACR recommendations for initiating treatment and addressing treatment failures.

Released: June 7, 2016

In this video module, Gregg J. Silverman, MD, and Sergio Schwartzman, MD, discuss approaches to integrating the latest ACR recommendations for initiating treatment and addressing treatment failures in rheumatoid arthritis.

Gregg J. Silverman, MD
Program Director
Sergio Schwartzman, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: June 7, 2016 Expiration: June 6, 2017

JAK Inhibitors

In this downloadable slideset, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.

Released: August 1, 2016

In this video module, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.

William F. C. Rigby, MD Gregg J. Silverman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 1, 2016 Expiration: July 31, 2017

ClinicalThought

Musculoskeletal ultrasound is a great tool for monitoring patients’ disease and specifically for visualizing disease damage and subclinical inflammation.

Cesar E. Fors Nieves, MD Released: April 21, 2016

The updated ACR guideline encourages us to reconsider the use of glucocorticoids for patients with RA. Here’s my take.

Gregg J. Silverman, MD Released: June 9, 2016

Consideration of tapering RA therapy is a careful balance between sustained remission and drug tolerability. Here is my take on determining when it is appropriate and which agents to taper.

Eric M. Ruderman, MD Released: July 14, 2016

Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.

Roy Fleischmann, MD Released: September 9, 2016
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Lilly USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?